Menu Search
Equities

enVVeno Medical Corp

5HJ:FRA

enVVeno Medical Corp

Actions
  • Price (EUR)3.16
  • Today's Change0.06 / 1.94%
  • Shares traded150.00
  • 1 Year change-13.19%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:06 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year enVVeno Medical Corp had revenues remain flat at 0.00, though the company grew net income from a loss of 24.67m to a smaller loss of 23.52m.
Gross margin--
Net profit margin--
Operating margin--
Return on assets-54.12%
Return on equity-58.76%
Return on investment-57.23%
More ▼

Cash flow in USDView more

In 2023, cash reserves at enVVeno Medical Corp fell by 935.00k. Cash Flow from Financing totalled 25.79m or -- of revenues. In addition the company used 18.86m for operations while cash used for investing totalled 7.87m.
Cash flow per share-1.32
Price/Cash flow per share--
Book value per share2.70
Tangible book value per share2.70
More ▼

Balance sheet in USDView more

enVVeno Medical Corp has little financial risk as the capital structure does not rely on leverage.
Current ratio22.01
Quick ratio--
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.